Stricter regulations, pricing control slow down pharma sector growth

The fifth part of the series looks at what's ailing the pharma sector

Rajesh Desai (name changed on request) is pensive. Only four months into his new job in the quality assurance department at pharma company Ratnamani Healthcare, Desai has seen the staff level fall from 12 to below 10.

What worries him is that there are no plans to replace his two colleagues.

Working at the company’s unit at one of the largest clusters in Changodar in Ahmedabad, Desai blames the slowdown. He can see it in the declining batches of parenteral (drugs intended to be administered via infusion or injection) arriving for quality checks. As against 5-6 batches of the drug undergoing quality